comparemela.com

Latest Breaking News On - Drug administration approved indication - Page 1 : comparemela.com

Chiesi Global Rare Diseases Announces Updated U S Prescribing Information for FERRIPROX® (deferiprone)

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomChiesi farmaceuticiB corpBerry company public relationsGroup chiesiChiesi groupGroup researchUs food drug administration approved indicationGlobal rare diseasesPrescribing informationDrug administration approved indicationImportant safetyDiamond blackfanBenefit corporationGlobal rare

Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),.

United statesUnited kingdomChiesi farmaceuticiGiacomo chiesiFernando trictaB corpBerry company public relationsGroup chiesiChiesi groupHealth canadaGroup researchUs food drug administration approved indicationGlobal rare diseasesChiesi global rareDrug administration approved indicationImportant safety

Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),.

United statesUnited kingdomChiesi farmaceuticiGiacomo chiesiFernando trictaB corpBerry company public relationsGroup chiesiChiesi groupHealth canadaGroup researchUs food drug administration approved indicationGlobal rare diseasesChiesi global rareDrug administration approved indicationImportant safety

vimarsana © 2020. All Rights Reserved.